Table 3.
Baseline characteristics of patients with hypertension, microalbuminuria, and type 2 diabetes followed from baseline to 24 weeks. All figures are means (SD) unless stated otherwise
| Candesartan | Lisinopril | Candesartan and lisinopril | |
|---|---|---|---|
| No of patients* | 66 | 64 | 67 |
| Age (years) | 59.7 (9.9) | 59.9 (9.0) | 59.8 (8.7) |
| No of men | 48 | 43 | 37 |
| Body mass index (kg/m2) | 31.0 (4.2) | 29.6 (3.7) | 30.2 (4.2) |
| Duration of hypertension (years) | 8.3 (8.9) | 7.9 (8.1) | 9.7 (9.3) |
| Duration of diabetes (years) | 10.0 (7.7) | 8.3 (7.0) | 9.1 (7.7) |
| Systolic blood pressure (mm Hg) | 163.3 (19.0) | 163.0 (17.2) | 161.7 (16.7) |
| Diastolic blood pressure (mm Hg) | 96.6 (6.9) | 96.2 (5.2) | 94.8 (6.4) |
| Urinary albumin:creatinine ratio (mg/mmol)† | 7.2 (1.1) | 5.9 (1.2) | 5.6 (1.1) |
| Serum creatinine (μmol/l) | 88.3 (18.5) | 85.6 (16.7) | 82.4 (18.1) |
| Creatinine clearance (ml/min) | 103.5 (38.4) | 96.8 (28.9) | 98.4 (32.9) |
| Haemoglobin A1c (%) | 7.5 (1.3) | 7.6 (1.7) | 7.6 (1.2) |
| ACE genotype (DD/ID/II/ not known) | 18/32/8/8 | 21/27/12/4 | 21/27/14/5 |
*
Two patients lost to follow up (see text for details).
†
Geometric mean (tolerance factors).